vTv Therapeutics Announces 2025 First Quarter Financial Results and Provides Corporate Update
Provided By GlobeNewswire
Last update: May 15, 2025
Ongoing screening in CATT1 Phase 3 trial evaluating cadisegliatin in patients with type 1 diabetes (T1D)
Topline Phase 3 data for cadisegliatin expected in 2H 2026
Read more at globenewswire.comNASDAQ:VTVT (11/13/2025, 4:30:02 PM)
31.27
+0.27 (+0.87%)
Find more stocks in the Stock Screener
